2281. Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014.
作者: Ola Olén.;Johan Askling.;Michael C Sachs.;Martin Neovius.;Karin E Smedby.;Anders Ekbom.;Jonas F Ludvigsson.
来源: Gut. 2020年69卷3期453-461页
To examine all-cause and cause-specific mortality in adult-onset and elderly-onset IBD and to describe time trends in mortality over the past 50 years.
2282. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis.
作者: Alasdair J Scott.;James L Alexander.;Claire A Merrifield.;David Cunningham.;Christian Jobin.;Robert Brown.;John Alverdy.;Stephen J O'Keefe.;H Rex Gaskins.;Julian Teare.;Jun Yu.;David J Hughes.;Hans Verstraelen.;Jeremy Burton.;Paul W O'Toole.;Daniel W Rosenberg.;Julian R Marchesi.;James M Kinross.
来源: Gut. 2019年68卷9期1624-1632页
In this consensus statement, an international panel of experts deliver their opinions on key questions regarding the contribution of the human microbiome to carcinogenesis.
2283. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
作者: Lena Schleier.;Maximilian Wiendl.;Karin Heidbreder.;Marie-Theres Binder.;Raja Atreya.;Timo Rath.;Emily Becker.;Anja Schulz-Kuhnt.;Annette Stahl.;Lisa Lou Schulze.;Karen Ullrich.;Simon F Merz.;Lea Bornemann.;Matthias Gunzer.;Alastair J M Watson.;Clemens Neufert.;Imke Atreya.;Markus F Neurath.;Sebastian Zundler.
来源: Gut. 2020年69卷2期252-263页
To study the role of α4β7 integrin for gut homing of monocytes and to explore the biological consequences of therapeutic α4β7 inhibition with regard to intestinal wound healing.
2284. Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3.
作者: Masahiro Maeda.;Hideyuki Takeshima.;Naoko Iida.;Naoko Hattori.;Satoshi Yamashita.;Hiroshi Moro.;Yoshimi Yasukawa.;Kazuhiro Nishiyama.;Taiki Hashimoto.;Shigeki Sekine.;Genichiro Ishii.;Atsushi Ochiai.;Takeo Fukagawa.;Hitoshi Katai.;Yoshiharu Sakai.;Toshikazu Ushijima.
来源: Gut. 2020年69卷2期243-251页
Cancer-associated fibroblasts (CAFs), a major component of cancer stroma, can confer aggressive properties to cancer cells by secreting multiple factors. Their phenotypes are stably maintained, but the mechanisms are not fully understood. We aimed to show the critical role of epigenetic changes in CAFs in maintaining their tumour-promoting capacity and to show the validity of the epigenomic approach in identifying therapeutic targets from CAFs to starve cancer cells.
2285. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
作者: Hong Jiang.;Xiuting Liu.;Brett L Knolhoff.;Samarth Hegde.;Kyung Bae Lee.;Hongmei Jiang.;Ryan C Fields.;Jonathan A Pachter.;Kian-Huat Lim.;David G DeNardo.
来源: Gut. 2020年69卷1期122-132页
We investigated how pancreatic cancer developed resistance to focal adhesion kinase (FAK) inhibition over time.
2286. Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis.
作者: Oliver Krenkel.;Jana Hundertmark.;Ali T Abdallah.;Marlene Kohlhepp.;Tobias Puengel.;Tilmann Roth.;Diogo Philippini Pontual Branco.;Jana C Mossanen.;Tom Luedde.;Christian Trautwein.;Ivan G Costa.;Frank Tacke.
来源: Gut. 2020年69卷3期551-563页
Bone marrow-derived myeloid cells accumulate in the liver as monocytes and macrophages during the progression of obesity-related non-alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH). Myeloid cells comprise heterogeneous subsets, and dietary overnutrition may affect macrophages in the liver and bone marrow. We therefore aimed at characterising in depth the functional adaptations of myeloid cells in fatty liver.
2287. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
作者: Man Liu.;Jingying Zhou.;Xiaoyu Liu.;Yu Feng.;Weiqin Yang.;Feng Wu.;Otto Ka-Wing Cheung.;Hanyong Sun.;Xuezhen Zeng.;Wenshu Tang.;Myth T S Mok.;John Wong.;Philip Chun Yeung.;Paul Bo San Lai.;Zhiwei Chen.;Hongchuan Jin.;Jie Chen.;Stephen Lam Chan.;Anthony W H Chan.;Ka Fai To.;Joseph J Y Sung.;Minhu Chen.;Alfred Sze-Lok Cheng.
来源: Gut. 2020年69卷2期365-379页
Hepatocellular carcinoma (HCC), mostly developed in fibrotic/cirrhotic liver, exhibits relatively low responsiveness to immune checkpoint blockade (ICB) therapy. As myeloid-derived suppressor cell (MDSC) is pivotal for immunosuppression, we investigated its role and regulation in the fibrotic microenvironment with an aim of developing mechanism-based combination immunotherapy.
2288. Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.
作者: Katharina Herzog.;Simonetta Bandiera.;Sophie Pernot.;Catherine Fauvelle.;Frank Jühling.;Amélie Weiss.;Anne Bull.;Sarah C Durand.;Béatrice Chane-Woon-Ming.;Sébastien Pfeffer.;Marion Mercey.;Hervé Lerat.;Jean-Christophe Meunier.;Wolfgang Raffelsberger.;Laurent Brino.;Thomas F Baumert.;Mirjam B Zeisel.
来源: Gut. 2020年69卷2期380-392页
Infection of human hepatocytes by the hepatitis C virus (HCV) is a multistep process involving both viral and host factors. microRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression. Given that miRNAs were indicated to regulate between 30% and 75% of all human genes, we aimed to investigate the functional and regulatory role of miRNAs for the HCV life cycle.
2289. Leaky gut: mechanisms, measurement and clinical implications in humans.
The objectives of this review on 'leaky gut' for clinicians are to discuss the components of the intestinal barrier, the diverse measurements of intestinal permeability, their perturbation in non-inflammatory 'stressed states' and the impact of treatment with dietary factors. Information on 'healthy' or 'leaky' gut in the public domain requires confirmation before endorsing dietary exclusions, replacement with non-irritating foods (such as fermented foods) or use of supplements to repair the damage. The intestinal barrier includes surface mucus, epithelial layer and immune defences. Epithelial permeability results from increased paracellular transport, apoptosis or transcellular permeability. Barrier function can be tested in vivo using orally administered probe molecules or in vitro using mucosal biopsies from humans, exposing the colonic mucosa from rats or mice or cell layers to extracts of colonic mucosa or stool from human patients. Assessment of intestinal barrier requires measurements beyond the epithelial layer. 'Stress' disorders such as endurance exercise, non-steroidal anti-inflammatory drugs administration, pregnancy and surfactants (such as bile acids and dietary factors such as emulsifiers) increase permeability. Dietary factors can reverse intestinal leakiness and mucosal damage in the 'stress' disorders. Whereas inflammatory or ulcerating intestinal diseases result in leaky gut, no such disease can be cured by simply normalising intestinal barrier function. It is still unproven that restoring barrier function can ameliorate clinical manifestations in GI or systemic diseases. Clinicians should be aware of the potential of barrier dysfunction in GI diseases and of the barrier as a target for future therapy.
2292. HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer.
作者: Chang Xu.;Wen Fong Ooi.;Aditi Qamra.;Jing Tan.;Benjamin Yan-Jiang Chua.;Shamaine Wei Ting Ho.;Kakoli Das.;Zul Fazreen Adam Isa.;Zhimei Li.;Xiaosai Yao.;Tingdong Yan.;Manjie Xing.;Kie Kyon Huang.;Joyce Suling Lin.;Tannistha Nandi.;Su Ting Tay.;Ming Hui Lee.;Angie Lay Keng Tan.;Xuewen Ong.;Hassan Ashktorab.;Duane Smoot.;Shang Li.;Shyh-Chang Ng.;Bin Tean Teh.;Patrick Tan.
来源: Gut. 2020年69卷2期231-242页
Gastric cancer (GC) is a leading cause of cancer mortality. Previous studies have shown that hepatocyte nuclear factor-4α (HNF4α) is specifically overexpressed in GC and functionally required for GC development. In this study, we investigated, on a genome-wide scale, target genes of HNF4α and oncogenic pathways driven by HNF4α and HNF4α target genes.
2295. Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates.
The impact of a screening programme on colorectal cancer (CRC) incidence in its target population depends on several variables, including coverage with invitations, participation rate, positivity rate of the screening test, compliance with an invitation to second-level assessment and endoscopists' sensitivity. We propose a synthetic indicator that may account for all the variables influencing the potential impact of a screening programme on CRC incidence.
2296. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice.
作者: Joana Torres.;Jianzhong Hu.;Akihiro Seki.;Caroline Eisele.;Nilendra Nair.;Ruiqi Huang.;Leonid Tarassishin.;Bindia Jharap.;Justin Cote-Daigneault.;Qixing Mao.;Ilaria Mogno.;Graham J Britton.;Mathieu Uzzan.;Ching-Lynn Chen.;Asher Kornbluth.;James George.;Peter Legnani.;Elana Maser.;Holly Loudon.;Joanne Stone.;Marla Dubinsky.;Jeremiah J Faith.;Jose C Clemente.;Saurabh Mehandru.;Jean-Frederic Colombel.;Inga Peter.
来源: Gut. 2020年69卷1期42-51页
Prenatal and early life bacterial colonisation is thought to play a major role in shaping the immune system. Furthermore, accumulating evidence links early life exposures to the risk of developing IBD later in life. We aimed to assess the effect of maternal IBD on the composition of the microbiome during pregnancy and on the offspring's microbiome.
2298. A blood-based prognostic biomarker in IBD.
作者: Daniele Biasci.;James C Lee.;Nurulamin M Noor.;Diana R Pombal.;Monica Hou.;Nina Lewis.;Tariq Ahmad.;Ailsa Hart.;Miles Parkes.;Eoin F McKinney.;Paul A Lyons.;Kenneth G C Smith.
来源: Gut. 2019年68卷8期1386-1395页
We have previously described a prognostic transcriptional signature in CD8 T cells that separates patients with IBD into two phenotypically distinct subgroups, termed IBD1 and IBD2. Here we sought to develop a blood-based test that could identify these subgroups without cell separation, and thus be suitable for clinical use in Crohn's disease (CD) and ulcerative colitis (UC).
|